Quick Answer
Spero Therapeutics, Inc. reported Stockholders Equity of $59.02 million for fiscal year 2025.
Spero Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $59.02M | +28.0% |
| 2024 | $46.12M | -56.9% |
| 2023 | $106.89M | +40.8% |
| 2022 | $75.93M | -14.0% |
| 2021 | $88.29M | -33.1% |
| 2020 | $132.04M | +77.1% |
| 2019 | $74.57M | -35.4% |
| 2018 | $115.50M | +36.5% |
| 2017 | $84.60M | +286.2% |
| 2016 | -$45.44M | -144.9% |
| 2015 | -$18.55M | -203.5% |
| 2014 | -$6.11M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.49M | -59.6% | -19.3% |
| June 30, 2025 | $32.83M | -59.2% | -2.9% |
| March 31, 2025 | $33.81M | -64.9% | -26.7% |
| December 31, 2024 | $46.12M | -56.9% | -29.6% |
| September 30, 2024 | $65.51M | +22.0% | -18.6% |
| June 30, 2024 | $80.50M | +46.9% | -16.4% |
| March 31, 2024 | $96.25M | +48.4% | -10.0% |
| December 31, 2023 | $106.89M | +40.8% | +99.0% |
- Spero Therapeutics, Inc. showed an increase of +28.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2014–2025 period, Spero Therapeutics, Inc.’s stockholders equity has grown by 1065.5% (from -$6.11 million to $59.02 million).
- The most recent figure is from Spero Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: